Document Detail


Drug screening for Huntington's disease and other neurodegenerative disorders.
MedLine Citation:
PMID:  20858196     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntington's disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Authors:
Hemant Varma
Related Documents :
23417246 - Impact of microbes on autoimmune diseases.
20809066 - Brain iron metabolism and its perturbation in neurological diseases.
20423336 - Mitochondria as pharmacological targets.
17316816 - Therapeutic rna interference for neurodegenerative diseases: from promise to progress.
12718396 - Effect of genotype and root colonization in biological control of fusarium wilts in pig...
19000536 - Complement, roles in renal disease and modulation for therapy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current molecular pharmacology     Volume:  3     ISSN:  1874-4702     ISO Abbreviation:  Curr Mol Pharmacol     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-15     Completed Date:  2011-03-01     Revised Date:  2012-04-18    
Medline Journal Info:
Nlm Unique ID:  101467997     Medline TA:  Curr Mol Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  164-73     Citation Subset:  IM    
Affiliation:
Department of Biological Sciences, Columbia University, 614 Fairchild Building, New York, NY 10027, USA. hv2108@columbia.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Apoptosis
Disease Models, Animal
Drug Evaluation, Preclinical
High-Throughput Screening Assays
Huntington Disease / drug therapy*
Neurodegenerative Diseases / drug therapy*
Protein Processing, Post-Translational
Proteins / chemistry,  metabolism,  toxicity
Reactive Oxygen Species / metabolism
Small Molecule Libraries / chemistry*,  therapeutic use
Chemical
Reg. No./Substance:
0/Proteins; 0/Reactive Oxygen Species; 0/Small Molecule Libraries

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Edible plants, their secondary metabolites and antiobesogenic potential.
Next Document:  Biological activities of natural and engineered cyclotides, a novel molecular scaffold for peptide-b...